嘉寓股份(300117.SZ):持股5%以上股東協議轉讓股份交易價格確定為2.916元/股
格隆匯2月7日丨嘉寓股份(300117.SZ)公佈,公司持股5%以上的股東李蘭於2019年11月29日分別與雷小雪、王金秀簽訂了《股票轉讓協議》(“原協議”),為明確交易價格,李蘭與雷小雪、王金秀分別於2020年1月11日簽訂《股票轉讓協議》之《補充協議》(“補充協議”)。
因近期股票價格發生重大變化,經甲乙雙方友好協商於2020年2月5日簽訂《變更協議》,交易價格確定為《變更協議》簽署前一天收盤價格的90%,即2.916元/股。變更協議未涉及的內容,以原協議為準,《補充協議》作廢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.